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Abstract
Aim Diaper dermatitis (DD) is an inflammatory
irritating condition that is common in infants. Most
cases are associated with the yeast colonization of
Candida or diaper dermatitis candidiasis (DDC), and
therefore, the signs and symptoms improve with
antimycotic treatment. Sertaconazole is a broad-spec-
trum third-generation imidazole derivative that is
effective and safe for the treatment for superficial
mycoses, such as tineas, candidiasis, and pityriasis
versicolor. Our goal was to assess the efficacy and
safety of sertaconazole cream (2 %) in DDC.
Materials and methods Twenty-seven patients with
clinical and mycological diagnosis of DDC were
enrolled and treated with 2 daily applications for
14 days and were followed-up for 2 further weeks.
Results Three etiologic agents were isolated: Candida
albicans in 88.8 %, Candida parapsilosis in 7.3 %, and
Candida glabrata in 3.2 %. There was an average
symptom reduction from 7.1 to 3.2 in the middle of
treatment and to 1.2 and 0.4 units at the end of treatment
and follow-up, respectively. The treatment evaluation at
the end of the follow-up period showed a total clinical
and mycological cure in 88.8 %, improvement in 3.7 %,
and failure in 7.4 %. There was side effect (3.7 %) of
skin irritation, but the drug was not discontinued.
Conclusions Based on its safety and effectiveness,
sertaconazole cream may be considered a new alter-
native for DDC treatment.
Keywords Candidiasis  Candida  Candida
albicans  Diaper dermatitis  Imidazole 
Sertaconazole
Introduction
Diaper dermatitis (DD) is a highly frequent condition
in infants, particularly at 1–15 months of age. Its onset
occurred in the 1960s with the development of
disposable diapers. It is an irritating and inflammatory
acute dermatitis in the perineal and perianal areas
resulting from the occlusion and irritation caused by
diapers. DD is directly influenced by a series of
factors, such as excessive humidity and skin macer-
ation, which regularly tends to show a change in
pH, thereby making it more alkaline. This is due to
urea transformation into ammonium hydroxide, which
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favors the loss of the skin barrier and subsequent
colonization by various microorganisms [1–4].
Colonization by different Candida species, pre-
dominantly Candida albicans, occurs in 70–80 % of
DDs, and therefore, it may be considered diaper
dermatitis candidiasis (DDC), which is also called
diaper rash Candida. Clinically, this condition occurs
in the region covered by the diaper, affecting the
gluteal area, perineum, groin, and, occasionally, part
of the genitalia. In terms of morphology, it shows
erythematous, scaly, macerated plaques with edema,
occasionally accompanied by vesicles and pustules. It
has symptoms of burning and itching, but these data
are hard to evaluate because they occur in young
children [5]. It should be noted that DD is an
inflammatory and irritating acute condition that is
not included within mycoses; its association with
different yeasts derives from its colonization [6, 7]. In
general, DD may be treated with desiccants and inert
substances. However, when the presence of Candida
yeasts is confirmed, it is necessary to provide antimy-
cotic treatment, which regularly tends to improve
signs and symptoms, together with an explanation that
diapers should be changed more frequently, desiccants
should be used, and humidity and maceration should
be avoided. [4, 7, 8].
Sertaconazole nitrate is a broad-spectrum third-
generation benzothiophene imidazole against derma-
tophytes, Candida-type yeasts, filamentous fungi, and
some bacteria [9, 10]. It is used for the treatment for
various tineas, candidiasis (vaginal), and pityriasis
versicolor. Its antimycotic action is based on its
fungistatic and fungicidal action, with long skin
perdurability for up to 72 h. Its mechanism of action
is based on inhibiting cytochrome p-450, on which
ergosterol synthesis is dependent. Ergosterol is the
main component of the fungal membrane. Its phar-
macodynamics has been described with good tolera-
bility, few side effects, and high efficacy against major
superficial mycoses [10, 11].
Based on the properties of sertaconazole nitrate
2 %, we decided to conduct an efficacy and safety
study in patients with Candida colonization in DD.
Materials and Methods
A descriptive, prospective, open-label, and non-com-
parative study to evaluate the efficacy and safety of
sertaconazole cream 2 % in patients with DDC was
conducted. Children from the dermatology units of the
Hospital General de Me´xico OD (Mexico General
Hospital) and the Hospital Infantil de Me´xico (Mexico
Children’s Hospital) were enrolled. Parents or legal
guardians accepted to take part in the study in writing,
and the protocol was followed based on the Declara-
tion of Helsinki and its subsequent amendments.
The study design included four mandatory visits:
baseline Visit 1 at the beginning of the study;
intermediate Visit 2, after 7 days of medication; final
Visit 3 after 14 days of medication and evaluation one
day later without medication (Day 15); and follow-up
Visit 4 after 14 days without medication. Clinical
evaluation was performed in all 4 visits, and myco-
logical evaluation took place in Visits 1, 3, and 4. The
study scheme is shown in Fig. 1.
Inclusion criteria: male or female children, between 2
and 24 months of DDC. Only patients who had the
condition for less than 4 months were included. Four
signs were evaluated clinically: erythema, scaling,
maceration, and edema. Each of these signs was scored
0–3, with the following codes: 0 = normal or without
clinical data; 1 = mild; 2 = moderate; and 3 = severe.
The following mycological studies were conducted:
Direct examination with KOH 10 % to show mycolog-
ical elements it is meaning the presence of pseudohyp-
hae and/or blastoconidia; isolation of Candida strains in
Sabouraud dextrose agar and CHROMagar-Candida
media. Once obtained, the strains were identified by the
commercial API-yeast 20 system.
Exclusion criteria: patients who received topical
antifungal within 2 months; patients with DD for more
than 4 months; patients with associated conditions in
the same region, such as associated bacterial infection
(Streptococcus sp., Staphylococcus sp.), psoriasis,
contact dermatitis, immunosuppressed patients, and
patients on another type of topical medication in the
diaper area.
The mother, or person in charge of each child, was
instructed to apply sertaconazole cream 2 %. Two
applications, one in the morning and one at night, were
performed after washing the child and changing the
diaper. Each mother was given 2 tubes of sertaconaz-
ole cream 2 % on Visits 1 and 2. No other drug was
applied throughout the study, and the children were
washed with soap and water only. After Visit 3,
follow-up was made for 14 days without medication;
the tubes provided were collected on Visits 2 and 3.
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At the end of the study, a clinical evaluation was
performed based on the measurement parameters; cure
was considered: no clinical data and negative culture;
improvement: discrete clinical data and negative
culture; and failure: evident clinical data and positive
culture.
Statistical analysis: Sample size was determined by
recruitment time (4 months). The data obtained are
presented in percentage values and bar graphs.
Results
Twenty-seven—15 females and 12 males—cases of
DDC with clinical and mycological diagnosis that
complied with the inclusion criteria were enrolled.
The youngest patient was 2 months old and the oldest
was 22 months, with an average of 5.7 months. The
main demographic, clinical, and mycological data are
shown in Table 1; results from the clinical, therapeu-
tic, and mycological evaluations are shown in Table 2.
Discussion
Diaper dermatitis is one of the most common skin
conditions in the first months of life; its onset is due to
leaving diapers on for long periods or to sensitivity. Its
pathogenesis has been discussed for many years. The
most important roles are played by humidity and skin
maceration, as well as alkalinity resulting from urine
and feces [3, 12–16]. In most instances, correcting
these factors is enough for the skin to keep its balance.
However, when humidity and occlusion factors per-
sist, the skin barrier breaks and facilitates microbial
colonization, which may occur by different bacteria,
especially Staphylococcus aureus [5, 7]. Its main
complication is colonization by Candida yeasts; they
come from the intestine and are usually part of skin’s
normal flora, particularly near the genitalia [3, 6, 7].
For many authors, Candida yeasts are present only
as colonization, not as etiologic agents, and they are
usually present in 70–80 % of DD [5, 6]. Nevertheless,
when these yeasts have a virulent form (pseudohyp-
hae, hyphae and/or large clusters of blastoconidia),
they stop being associated with the flora and start to be
considered as a superficial candidiasis, affecting the
stratum corneum. In these cases, the use of antifungals
or antimycotics such as nystatin, azole derivatives
(clotrimazole, ketoconazole, etc.), or ciclopirox sig-
nificantly reduces the clinical signs and symptoms, but
it should be emphasized that, if humidity, maceration,
and occlusion factors persist, recurrence is common
[17–19].
This is an open-label, non-comparative study to
evaluate the effectiveness and safety of sertaconazole
cream. This imidazole derivative was used because of
its good effectiveness within in vitro studies and in
treating superficial and vaginal candidiasis, and its
broad-spectrum, perdurability, and good tolerance
[9, 11].
A demographic analysis of the data in Table 1
shows that both genders are balanced, and the average
age is 5.7 months. The literature indicates that DD
Fig. 1 Study treatment and follow-up scheme
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occurs between 1 and 15 months [3, 4, 7], with a
higher average between 2 and 9 months. It is impor-
tant to note that the mean duration of disease was
14.5 days because the limit was 4 months in our
inclusion criteria. This is because it is harder to correct
factors and get a treatment response in chronic DD
cases. Some studies, for example, Hoeger et al. [20]
take a limit of 6 months. It should be highlighted that
most included cases were in a mild (55 %) to moderate
(37 %) range, which also plays a role in getting a faster
response to treatment and correcting predisposing
factors.
From a mycological standpoint, it should be said
that all DD cases were associated with virulent forms
of Candida, that is, there were pseudohyphae in 26/27
patients (96.3 %) and it was only in one case (1/27;
3.7 %) that there was a significant cluster of yeasts
corresponding to C. glabrata, which is a species that
does not form these structures and its pathogenicity is
marked with the number of yeasts of blastoconidia.
C. albicans was predominant (88.8 %), similar to
reports in the literature, but it is noteworthy that two
further species were obtained: C. parapsilosis and
C. glabrata, both related to resistance to different
antifungals [21, 22].
Table 1 Main demographic, clinical, and mycological data
Data Results
Number of patients: 27 15 females (55 %)
12 males (45 %)
Age Youngest: 2 months
Oldest: 22 months
Average: 5.7 months




(based on the clinical
signs score)
Mild: 15 cases (55 %)
Moderate: 10 cases (37 %)
Severe: 2 cases (8 %)
Direct examination Pseudohyphae ? blastoconidia:
26/27 cases (96.3 %)
Blastoconidia (plenty)a 1/27
cases (3.7 %)






a The image of plenty blastoconidia only corresponded to the
C. glabrata isolate












7.1 3.2 1.2 0.4
Direct examination Ps ? B: 26 cases.
B: 1 case
NP Ps ? B: 1 case Ps ? B: 2 cases
Cultures C. albicans: 24
C. parapsilosis: 2
C. glabrata: 1













Failure: 2/27 (7.4 %)




NP not performed, Ps Pseudohyphae, B Blastoconidia
a Clinical signs (erythema, scaling, maceration, and edema), minimum average = 0, maximum average = 9
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Clinical, mycological, and therapeutic data may be
seen in Table 2. Given that most included cases were
mild or moderate, the overall average of clinical signs
(erythema, scaling, burning, and edema) was 7.1 units.
This is considered the baseline value, and it is clearly
seen that, at the 7-day assessment, it goes down to 3.2,
that is, more than 50 % of signs are considerably
decreased. By the end of treatment, the average is 1.2
units, and it is even lower during follow-up. This is
probably due to the same correction of predisposing
factors; this reduction in signs such as erythema and
edema may be due to sertaconazole’s good antimy-
cotic action, but also to its important proved anti-
inflammatory action [23, 24]. From a mycological
standpoint, only one case failed by the end of
treatment and two did during follow-up. According
to the cure criteria, at the end of follow-up, there was
clinical and mycological cure in 24/27 cases (88.8 %),
improvement (i.e., clinical data and no-yeast isolation)
in 1/27 case (3.7 %), and failure (persistence of
clinical data and new isolation of yeast) in 2/27 cases
(7.4 %). Failures corresponded to C. albicans species;
one case was considered severe, and the other was
considered moderate in the baseline classification.
There was only one adverse event (3.7 %) of derma-
titis at the end of treatment, with slightly increased
erythema. The mother considered it possibly due to the
medication and did not discontinue treatment. In the
follow-up visit, the child did not show any clinical data
and was considered a complete cure. The event was
reported as a possible side effect.
In other studies reported in the literature on the use of
antifungals in DD, the best outcomes are reported with
the use of topical antifungals for 2 weeks. Even though
ours is not a comparative study, it is similar to the study
by Hoeger et al. [20], in terms of design and clinical–
microbiological evaluation. They reported clotrimazole
superiority over nystatin with complete (clinical and
mycological) cure rates of 68.1 and 49.8 %, respec-
tively, with a statistically significant difference. This is a
study that enrolled more than 200 infants and used
miconazole 0.25 % [19] in ointment; good results were
also obtained particularly versus placebo.
Gallup et al. [25] conducted an open-label, non-
comparative study using ciclopirox suspension (0.77 %)
applied twice daily, but only for 7 days, and assessed
after 14 days. They obtained good results in total
success scores (p \ 0.047), with a significant reduction
in signs, symptoms, and mycological cure evaluation.
It is important to highlight that, even though
Candida DD is a very frequent entity, few papers
dealing with treatment are found in the literature.
However, the new breathable disposable diaper tech-
nology has proved to reduce Candida prevalence in
35–80 %. This is important because airing the diaper
area undoubtedly reduces yeast development in a
significant way [26].
In general, azole derivatives have a broad spectrum
of action in infections caused by dermatophytes and
yeasts. Sertaconazole nitrate is a benzothiophene
imidazole, a topical broad-spectrum antifungal devel-
oped for the treatment for skin and mucosal infections
[9–11]. It has a dual mechanism of action: firstly,
through ergosterol synthesis inhibition by blocking the
enzymatic pathway of cytochrome p-450, which acts
with cell growth; secondly, because it binds directly to
non-sterol lipids on the fungal membrane and inter-
feres with ligands from the intra-cellular contents,
thereby causing cell death. It is an effective fungicidal
and fungistatic agent. In addition, anti-inflammatory
properties have been described by reducing cytokine
secretion from activated lymphocytes, which controls
the inflammatory component of dermatophytosis and
candidiasis [1, 11].
Conclusions
Sertaconazole cream 2 % for the treatment for DD-
associated candidiasis achieved a [50 % reduction
in clinical signs after 7 days of treatment (from 7.1
to 3.2 units) and practically symptomless by the end
of treatment (0.4 units). It was effective for a
clinical–mycological cure in 88.8 %. There was a
possible side effect (3.7 %) of skin irritation that did
not call for drug discontinuation. Based on the
above, we conclude that sertaconazole cream is
a broad-spectrum third-generation imidazole with
great skin penetration and perdurability that may be
considered as an alternative for the treatment for
DD-associated candidiasis due to its high efficacy
and good safety.
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